Skip to main content

Atossa Therapeutics, Inc.

ATOS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001488039

No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Atossa Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of ATOS: Q3 2024 compared with Q4 2024
MeasureQ3 2024Of which not filed for Q4 2024Q4 2024Change
Holders86286+2
Shares27.3M11.8K29.9M+2.60M (+9.5%)
Value$41.6M$18.0K$28.3M−$13.3M (−32.0%)

2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Atossa Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to ATOS in Q4 2024
InstitutionSharesValue% of portfolio
HRT Financial LP31,501$29.0K0.00%
Millennium Management LLC29,149$27.5K0.00%
Gallagher Capital Advisors, LLC26,075$24.6K0.02%
Police & Firemen's Retirement System of New Jersey25,430$24.0K0.00%
Raymond James Financial Inc18,815$17.8K0.00%
Group One Trading, L.P.13,430$12.7K0.00%
CIBC World Markets Corp11,837$11.2K0.00%
SBI Securities Co., Ltd.1,565$1.48K0.00%
R Squared Ltd1,020$9630.00%
EverSource Wealth Advisors, LLC32$300.00%
Simplex Trading, LLC609$00.00%

Sold out (9)

Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of ATOS in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Wolverine Trading, LLC30,922$46.7K
MetLife Investment Management23,978$36.4K
Acadian Asset Management LLC14,586$22.0K
Squarepoint Ops LLC12,627$19.2K
Principal Financial Group Inc10,245$15.6K
Silicon Valley Capital Partners3,875$5.89K
Signaturefd, LLC400$608
Delos Wealth Advisors, LLC100$152
Capital Performance Advisors LLP25$38

Not filed for Q4 2024 yet (2)

Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ATOS in Q3 2024 that haven't filed for Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Raymond James Financial Services Advisors, Inc.10,815$16.4K
Planning Capital Management Corp1,000$1.52K